Mobile

This is an open-label, multicenter, nonrandomized Phase 1b study of oral administration of LY2157299 in combination with gemcitabine followed by a randomized, double-blind, Phase 2 study of oral admin...

Update Il y a 4 ans
Reference: EUCTR2011-000211-64

This is an open-label, multicenter, nonrandomized Phase 1b study of oral administration of LY2157299 in combination with gemcitabine followed by a randomized, double-blind, Phase 2 study of oral administration of LY2157299 monohydrate in combination with gemcitabine versus gemcitabine plus placebo

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Phase 2: To compare overall survival (OS) in patients with Stage II-IV unresectable pancreatic cancer when treated with the combination of LY2157299 monohydrate and gemcitabine with that of gemcitabine plus placebo.

Inclusion criteria

  • Phase 2: Advanced or Metastatic Unresectable Pancreatic Cancer

Links